<SEC-DOCUMENT>0001437749-25-038478.txt : 20251222
<SEC-HEADER>0001437749-25-038478.hdr.sgml : 20251222
<ACCEPTANCE-DATETIME>20251222085552
ACCESSION NUMBER:		0001437749-25-038478
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20251221
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251222
DATE AS OF CHANGE:		20251222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moleculin Biotech, Inc.
		CENTRAL INDEX KEY:			0001659617
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				474671997
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37758
		FILM NUMBER:		251589623

	BUSINESS ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
		BUSINESS PHONE:		713-300-5160

	MAIL ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mbrx20251221_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:mbrx="http://www.mbrx.com/20251221"><head>
	<title>mbrx20251221_8k.htm</title>
	<!-- Generated by ThunderDome Portal - 12/22/2025 1:12:28 PM -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20258K" name="dei:AmendmentFlag" id="ixv-289">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20258K" name="dei:EntityCentralIndexKey" id="ixv-290">0001659617</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="mbrx-20251221.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<xbrli:context id="d20258K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-12-21</xbrli:startDate>
<xbrli:endDate>2025-12-21</xbrli:endDate>
</xbrli:period>
</xbrli:context>



</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>WASHINGTON, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <ix:nonNumeric contextRef="d20258K" name="dei:DocumentType" id="ixv-300">8-K</ix:nonNumeric> </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): <ix:nonNumeric contextRef="d20258K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-301">December 21, 2025</ix:nonNumeric> </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityRegistrantName" id="ixv-302">MOLECULIN BIOTECH, INC.</ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact Name of Registrant as Specified in its Charter)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:middle;width:17.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="text-transform:uppercase;"><b><ix:nonNumeric contextRef="d20258K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-303">Delaware</ix:nonNumeric></b></span></div>
			</td>
			<td style="vertical-align:middle;width:17.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityFileNumber" id="ixv-304">001-37758</ix:nonNumeric></b></div>
			</td>
			<td style="vertical-align:middle;width:17.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityTaxIdentificationNumber" id="ixv-305">47-4671997</ix:nonNumeric></b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or Other Jurisdiction of</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporation or Organization)</div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Commission File No.)</div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="logosm01.jpg" src="logosm01.jpg"/></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressAddressLine1" id="ixv-306">5300 Memorial Drive, Suite 950</ix:nonNumeric>, <ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressCityOrTown" id="ixv-307">Houston</ix:nonNumeric>,</b>&#160;<b><ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressStateOrProvince" id="ixv-308">TX</ix:nonNumeric> <ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressPostalZipCode" id="ixv-309">77007</ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Address of principal executive offices and zip code)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(<ix:nonNumeric contextRef="d20258K" name="dei:CityAreaCode" id="ixv-310">713</ix:nonNumeric>) <ix:nonNumeric contextRef="d20258K" name="dei:LocalPhoneNumber" id="ixv-311">300-5160</ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Former name or former address, if changed from last report)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see </i>General Instruction A.2. below):</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="ixv-312">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="ixv-313">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="ixv-314">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="ixv-315">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company <ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-316">&#9744;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0); vertical-align: top; width: 19.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 1pt;"><b>Title of each class</b></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 13.7%; border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 1pt;"><b>Trading Symbol (s)</b></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 19.4%; border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 1pt;"><b>Name of each exchange on which registered</b></div>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 19.5%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 1pt;"><ix:nonNumeric contextRef="d20258K" name="dei:Security12bTitle" id="ixv-317">Common Stock</ix:nonNumeric>, par value $.001 per share</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 13.7%; border-right: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 1pt;"><ix:nonNumeric contextRef="d20258K" name="dei:TradingSymbol" id="ixv-318">MBRX</ix:nonNumeric></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 19.4%; border-right: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 1pt;">The <ix:nonNumeric contextRef="d20258K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-319">NASDAQ</ix:nonNumeric> Stock Market LLC</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<div style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>Item 1.01 </b></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>Entry into a Material Definitive Agreement.</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On December 21, 2025, Moleculin Biotech, Inc. (the &#8220;Company&#8221;) entered into separate warrant amendment agreements (collectively, the &#8220;Warrant Amendment&#8221;) with the holders of the Company&#8217;s Series E warrants (the &#8220;Series E warrants&#8221;), Series F warrants (the &#8220;Series F warrants&#8221;), and Series G warrants (the &#8220;Series G warrants,&#8221; and collectively with the Series E warrants and Series F warrants, the &#8220;Warrants&#8221;). Pursuant to the Warrant Amendment, (A) the Warrants were amended to reduce the exercise price of the Warrants to $3.90 per share; and (B) the Series E warrants and Series F warrants were amended to delete the following sections immediately following the foregoing repricing: (i) a provision providing for the adjustment of the exercise price (and with respect to the Series E warrants, the number of shares issuable thereunder) of the Series E warrants and Series F warrants if the Company changes the exercise or conversion price of any outstanding convertible securities to a price per share less than the exercise price of the Series E warrants and Series F warrants then in effect; and (ii) a provision providing for the adjustment of the exercise price (and with respect to the Series E warrants, the number of shares issuable thereunder) of the Series E warrants and Series F warrants if the price of the Company&#8217;s common stock after the completion of a share split, share dividend, share combination, recapitalization or other similar transaction is less than the exercise price of the Series E warrants and Series F warrants then in effect. In addition, the Warrant Amendment modified the definition of Black Scholes Value in the Series E warrants and Series F warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The foregoing description of the form of Warrant Amendment, the amended and restated Series E warrant, the amended and restated Series F warrant and the amended and restated Series G warrant is not complete and each is qualified in its entirety by reference to the full text of the documents, copies of which are filed as Exhibit 10.1, 4.1,&#160;4.2, and 4.3, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<div style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>Item 8.01 </b></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>Other Events.</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As previously disclosed, on May 23, 2025, the Company received a letter from the staff of the Listing Qualifications Department (the &#8220;Staff&#8221;) of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;), which notified the Company that it did not comply with Nasdaq&#8217;s Listing Rule 5550(b)(1) (the &#8220;Listing Rule&#8221;), which requires that the Company maintain a minimum of $2.5 million in stockholders&#8217; equity, and that the Company also did not meet the alternatives of market value of listed securities or net income from continuing operations set forth in the Listing Rule.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Staff had previously granted the Company an extension until November 19, 2025 to regain compliance with the Listing Rule. On November 20, 2025, the Company received a delist determination letter from the Staff (the &#8220;Nasdaq Notice&#8221;) advising the Company that the Staff had determined that the Company had not regained compliance with the Listing Rule. Accordingly, the Staff indicated that unless the Company requested a hearing panel (a &#8220;Panel&#8221;) appeal of the delist determination its securities would be delisted. The Company appealed Nasdaq&#8217;s determination to a Panel, which stayed any suspension or delisting pending the Panel&#8217;s determination and any further extension the Panel may grant. The Panel hearing is currently scheduled for January 20, 2026.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Subsequent to the receipt of the Nasdaq Notice, the Company has undertaken the following steps to come into compliance with the Listing Rule: (i) on December 9, 2025, the Company completed a warrant inducement transaction pursuant to which it raised $6.8 million in gross proceeds from the exercise of warrants; (ii) the Company raised gross proceeds of approximately $1.1 million at an average price of approximately $8.31 per share pursuant to its at-the-market facility; and (iii) on December 21, 2025, the Company entered into the Warrant Amendment described in Item 1.01 of this Form 8-K with the holders of certain of its Series E warrants and Series F warrants, which amendments permitted the Company to account for such securities, which had previously been warrant liabilities, as equity.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of September 30, 2025, the Company had a stockholders&#8217; deficit of $26.9 million. As of the date hereof, after management takes into account the transactions described in the above paragraph, the Company&#8217;s stockholders&#8217; equity is in excess of $10.0 million.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<div style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>Item 9.01</b></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>Financial Statements and Exhibits.</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 45pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">(d)</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt;"><span style="text-decoration: underline;">Exhibits</span>.</div>
			</td>
		</tr>
		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 45pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.1</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt;"><a href="ex_901475.htm" style="-sec-extract:exhibit;">Form of Amended and Restated Series E Warrant</a></div>
			</td>
		</tr>
		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 45pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.2</div>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt;"><a href="ex_901476.htm" style="-sec-extract:exhibit;">Form of Amended and Restated Series F Warrant</a></div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 45pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.3</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_901551.htm" style="-sec-extract:exhibit;">Form of Amended and Restated Series G Warrant</a></td>
		</tr>
		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 45pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.1</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt;"><a href="ex_901477.htm" style="-sec-extract:exhibit;">Form of Warrant Amendment</a></div>
			</td>
		</tr>
		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 45pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">104</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline;">SIGNATURE</span></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tbody><tr>
			<td valign="top" style="width: 50%; ">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
			<td colspan="2" valign="top" style="width: 38%; "><b>MOLECULIN BIOTECH, INC.</b>&#160;</td>
			<td valign="top" style="width: 12%; ">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
		</tr>
		<tr>
			<td valign="top" style="width: 50%; ">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
			<td valign="top" style="width: 3%; ">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
			<td valign="top" style="width: 35%; ">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
			<td valign="top" style="width: 12%; ">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
		</tr>
		<tr>
			<td valign="top" style="width: 50%; ">&#160;</td>
			<td valign="top" style="width: 3%; ">&#160;</td>
			<td valign="top" style="width: 35%; ">&#160;</td>
			<td valign="top" style="width: 12%; ">&#160;</td>
		</tr>
		<tr>
			<td valign="top" style="width: 50%; ">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
			<td colspan="2" rowspan="1" valign="top" style="width: 3%; ">Date: December 22, 2025</td>
			<td valign="top" style="width: 12%; ">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
		</tr>
		<tr>
			<td valign="top" style="width: 50%; ">&#160;</td>
			<td colspan="2" valign="top" style="width: 3%; ">&#160;</td>
			<td valign="top" style="width: 12%; ">&#160;</td>
		</tr>
		<tr>
			<td align="left" style="width: 50%; text-align: left;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
			<td style="width: 3%; text-align: left" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </span></div>
			</td>
			<td align="left" style="nowrap: nowrap; width: 35%; BORDER-BOTTOM: #000000 1px solid" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&#160;</span>Jonathan P. Foster&#160;</div>
			</td>
			<td valign="top" style="width: 12%; ">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
		</tr>
		<tr>
			<td valign="top" style="width: 50%; ">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
			<td valign="top" style="width: 3%; ">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
			<td valign="top" style="width: 35%; ">Jonathan P. Foster&#160;</td>
			<td valign="top" style="width: 12%; ">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
		</tr>
		<tr>
			<td valign="top" style="width: 50%; ">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
			<td valign="top" style="width: 3%; ">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
			<td valign="top" style="width: 35%; ">Chief Financial Officer&#160;</td>
			<td valign="top" style="width: 12%; ">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex_901475.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<html><head>
	<title>ex_901475.htm</title>

	<!-- Generated by ThunderDome Portal - 12/21/2025 10:44:38 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 4.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:108pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AMENDED AND RESTATED SERIES E COMMON STOCK PURCHASE WARRANT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>MOLECULIN BIOTECH, INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Warrant Shares: [_______]&nbsp;</td>
			<td style="width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">New Issue Date: December __, 2025</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 33%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 33%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 33%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 33%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 33%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 33%;">Original Issue Date: June 23, 2025</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 72pt;">THIS AMENDED AND RESTATED SERIES E COMMON STOCK PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received, [_____________] or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholder Approval Date (the &#8220;<u>Initial Exercise Date</u>&#8221;) and on or prior to 5:00 p.m. (New York City time) on the five (5) year anniversary of the Initial Exercise Date, (the &#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase from Moleculin Biotech, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to [______] shares of Common Stock (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). The Company and the Holder each acknowledges and agrees that this Warrant amends and restates in its entirety and replaces that certain Series E Common Stock Purchase Warrant that was issued by the Company to the Holder on June 23, 2025, which is deemed cancelled as of the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><u>Section 1</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Affiliate</u>&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Amendment</u>&#8221; means the amendment to the Company&#8217;s certificate of incorporation that effects a reverse stock split or an increase in the authorized shares of Common Stock such that, following such reverse stock split or increase in authorized shares of Common Stock, there are authorized and unissued shares of Common Stock sufficient for the issuance of the Warrant Shares upon any adjustment to the Exercise Price pursuant to Section 3(e) and Section 3(f).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Authorized Share Approval</u>&#8221; means approval of the Amendment by the shareholders of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Authorized Share Increase Date</u>&#8221; means, subject to Authorized Share Approval, the date on which the Amendment is filed and accepted with the State of Delaware.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Board of Directors</u>&#8221; means the board of directors of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Business Day</u>&#8221; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; <u>provided</u>, <u>however</u>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#8220;stay at home&#8221;, &#8220;shelter-in-place&#8221;, &#8220;non-essential employee&#8221;&nbsp; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Commission</u>&#8221; means the United States Securities and Exchange Commission.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Common Stock</u>&#8221; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Common Stock Equivalents</u>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Floor Price</u>&#8221; means a price equal to $3.00, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the Issue Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Person</u>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Purchase Agreement</u>&#8221; means the securities purchase agreement, dated as of June 20, 2025 by and between the Company and each of the purchasers signatory thereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Registration Statement</u>&#8221; means the Company&#8217;s registration statement on Form S-1 (File No. 333-287727).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">&#8220;<u>Stockholder Approval</u>&#8221; means such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market (or any successor entity) from the stockholders of the Company with respect to issuance of all of the Warrants and the Warrant Shares upon the exercise thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">&#8220;<u>Stockholder Approval Date</u>&#8221; means the date on which Stockholder Approval is received and deemed effective under Delaware law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Subsidiary</u>&#8221; means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Trading Day</u>&#8221; means a day on which the Common Stock is traded on a Trading Market.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Trading Market</u>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange (or any successors to any of the foregoing).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Transfer Agent</u>&#8221; means VStock Transfer, LLC, the current transfer agent of the Company, with a mailing address of 18 Lafayette Place, Woodmere, New York 11598 and an email address of info@vstocktransfer.com, and any successor transfer agent of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Warrants</u>&#8221; means this Warrant and other Series E Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Section 2</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise on the Trading Day of receipt of such notice. <b>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise Price</u>. The exercise price per share of Common Stock under this Warrant shall be $3.90, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Cashless Exercise</u>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(A)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">= as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221;&nbsp;(as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;<u>Bloomberg</u>&#8221;) as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221;&nbsp;on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221;&nbsp;on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221;&nbsp;on such Trading Day;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(B)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">= the Exercise Price of this Warrant, as adjusted hereunder; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(X)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">= the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary to this Section 2(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">d)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>Mechanics of Exercise</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">i.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221;&nbsp;means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">iii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">iv.&nbsp;&nbsp;&nbsp;&nbsp;<u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">v.&nbsp;&nbsp;&nbsp;&nbsp;<u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">vi.&nbsp;&nbsp;&nbsp;&nbsp;<u>Charges, Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">vii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Holder</u><u>&#8217;</u><u>s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<sup style="vertical-align:top;line-height:120%;">st</sup> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Section 3</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Adjustments</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Stock Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding Common Stock or greater than 50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires greater than 50% of the outstanding shares of Common Stock or greater than 50% of the voting power of the common equity of the Company (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; <u>provided</u>,<i> </i><u>however</u>, that, if the Fundamental Transaction is not approved by the Company's Board of Directors nor otherwise within the Company&#8217;s control, the Holder shall only be entitled to receive from the Company or any Successor Entity, as of the date of the consummation of such Fundamental Transaction, the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration (as considered by the Company&#8217;s Board of Directors) be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; <u>provided</u>, <u>further</u>, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &#8220;<u>Black Scholes Value</u>&#8221; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the "OV" function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction, or, if the Fundamental Transaction is not publicly announced, the date the Fundamental Transaction is consummated, for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of this Warrant as of such date of request, (ii) an expected volatility equal to the greater of (1) the 100 day volatility as obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, and (2) 100%, (iii) the underlying price per share used in such calculation shall be the greater of (a) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (b) the higher of (1) the VWAP immediately preceding the public announcement of the applicable contemplated Fundamental Transaction and (2) the VWAP immediately preceding the consummation of the applicable Fundamental Transaction, (iv) a remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, and (v) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five Business Days of the Holder&#8217;s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &#8220;Company&#8221; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(d) regardless of (i) whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustment Upon Issuance of Shares of Common Stock</u>. If and whenever on or after the Issue Date, the Company issues or sells (or enters into any agreement to grant, issue or sell), or in accordance with this Section 3(e) is deemed to have issued or sold, any shares of Common Stock and/or Common Stock Equivalents (including the issuance or sale of shares of Common Stock owned or held by or for the account of the Company, but excluding any Exempt Issuance (as defined in the Purchase Agreement)) for a consideration per share (the &#8220;<u>New Issuance Price</u>&#8221;) less than a price equal to the Exercise Price in effect immediately prior to such issuance or sale or deemed issuance or sale (such Exercise Price then in effect is referred to herein as the &#8220;<u>Applicable Price</u>&#8221;) (the foregoing a &#8220;<u>Dilutive Issuance</u>&#8221;), then simultaneously with the consummation (or, if earlier, the announcement) of each such Dilutive Issuance, the Exercise Price then in effect shall be reduced to an amount equal to the New Issuance Price; provided that the adjusted Exercise Price under this Section 3(e) shall not be less than the Floor Price. For all purposes of the foregoing (including, without limitation, determining the adjusted Exercise Price and the New Issuance Price under this Section 3(e)), the following shall be applicable:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;text-indent:36pt;">(i) <u>Issuance of Options</u>. If the Company in any manner grants or sells any rights, warrants or options to subscribe for or purchase shares of preferred stock and/or Common Stock or Common Stock Equivalents (&#8220;<u>Options</u>&#8221;) and the lowest price per share for which one share of Common Stock is at any time issuable upon the exercise of any such Option or upon conversion, exercise or exchange of any Common Stock Equivalents issuable upon exercise of any such Option or otherwise pursuant to the terms thereof is less than the Applicable Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the granting or sale of such Option for such price per share. For purposes of this Section 3(e)(i), the &#8220;lowest price per share for which one share of Common Stock is issuable upon the exercise of any such Options or upon conversion, exercise or exchange of any Common Stock Equivalents issuable upon exercise of any such Option or otherwise pursuant to the terms thereof&#8221; shall be equal to (1) the lower of (x) the sum of the lowest amounts of consideration (if any) received or receivable by the Company with respect to any one share of Common Stock upon the granting or sale of such Option, upon exercise of such Option and upon conversion, exercise or exchange of any Common Stock Equivalents issuable upon exercise of such Option or otherwise pursuant to the terms thereof and (y) the sum of the consideration received or receivable by the Company with respect to any one share of Common Stock upon the granting or sale of such Option and the lowest exercise price set forth in such Option for which one share of Common Stock is issuable upon the exercise of any such Options or upon conversion, exercise or exchange of any Common Stock Equivalents issuable upon exercise of any such Option or otherwise pursuant to the terms thereof minus (2) the sum of all amounts paid or payable to the holder of such Option (or any other Person) upon the granting, issuance or sale of such Option, upon exercise of such Option and upon conversion, exercise or exchange of any Common Stock Equivalents issuable upon exercise of such Option or otherwise pursuant to the terms thereof plus the value of any other consideration received or receivable by, or benefit conferred on, the holder of such Option (or any other Person). Except as contemplated below, no further adjustment of the Exercise Price shall be made upon the actual issuance of such shares of Common Stock or of such Common Stock Equivalents upon the exercise of such Options or otherwise pursuant to the terms of or upon the actual issuance of such shares of Common Stock upon conversion, exercise or exchange of such Common Stock Equivalents. This Section 3(e)(i) shall not apply to any Exempt Issuance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt;">(ii)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Issuance of Common Stock Equivalents</u>. If the Company in any manner issues or sells any Common Stock Equivalents and the lowest price per share for which one share of Common Stock is at any time issuable upon the conversion, exercise or exchange thereof or otherwise pursuant to the terms thereof is less than the Exercise Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the issuance or sale of such Common Stock Equivalents for such price per share. For the purposes of this Section 3(e)(ii), the &#8220;lowest price per share for which one share of Common Stock is issuable upon the conversion, exercise or exchange thereof or otherwise pursuant to the terms thereof&#8221; shall be equal to (1) the lower of (x) the sum of the lowest amounts of consideration (if any) received or receivable by the Company with respect to one share of Common Stock upon the issuance or sale of the Common Stock Equivalent and upon conversion, exercise or exchange of such Common Stock Equivalent or otherwise pursuant to the terms thereof and (y) the sum of the consideration received or receivable by the Company with respect to any one share of Common Stock upon the granting or sale of such Common Stock Equivalent and the lowest conversion price set forth in such Common Stock Equivalent for which one share of Common Stock is issuable upon conversion, exercise or exchange thereof or otherwise pursuant to the terms thereof minus (2) the sum of all amounts paid or payable to the holder of such Common Stock Equivalent (or any other Person) upon the issuance or sale of such Common Stock Equivalent plus the value of any other consideration received or receivable by, or benefit conferred on, the holder of such Common Stock Equivalent (or any other Person). Except as contemplated below, no further adjustment of the Exercise Price shall be made upon the actual issuance of such shares of Common Stock upon conversion, exercise or exchange of such Common Stock Equivalents or otherwise pursuant to the terms thereof, and if any such issuance or sale of such Common Stock Equivalents is made upon exercise of any Options for which adjustment of the Warrant has been or is to be made pursuant to other provisions of this Section 3(e), except as contemplated below, no further adjustment of the Exercise Price shall be made by reason of such issuance or sale.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;text-indent:36pt;">(iii)&nbsp; Reserved.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;text-indent:36pt;">(iv)&nbsp; &nbsp;&nbsp;<u>Calculation of Consideration Received</u>. If any Option and/or Common Stock Equivalent and/or Adjustment Right is issued in connection with the issuance or sale or deemed issuance or sale of any other securities of the Company (as reasonably determined jointly by the Holder and the Company, the &#8220;<u>Primary Security</u>&#8221; and such Option and/or Common Stock Equivalent and/or Adjustment Right, the &#8220;<u>Secondary Securities</u>&#8221; and, together with the Primary Security, each a &#8220;<u>Unit</u>&#8221;), together comprising one integrated transaction, the aggregate consideration per share of Common Stock with respect to such Primary Security shall be deemed to be the lowest of (x) the purchase price of such Unit, (y) if such Primary Security is an Option and/or Common Stock Equivalent, the lowest price per share for which one share of Common Stock is at any time issuable upon the exercise or conversion of the Primary Security in accordance with Section 3(e)(i) or 3(e)(ii) above and (z) the lowest VWAP on any Trading Day during the five (5) Trading Day period (the &#8220;<u>Adjustment Period</u>&#8221;) immediately following the public announcement of such Dilutive Issuance (for the avoidance of doubt, if such public announcement is released prior to the opening of the applicable Trading Market on a Trading Day, such Trading Day shall be the first Trading Day in such five Trading Day period and if this Warrant is exercised, on any given Exercise Date during any such Adjustment Period, solely with respect to such portion of this Warrant converted on such applicable Exercise Date, such applicable Adjustment Period shall be deemed to have ended on, and included, the Trading Day immediately prior to such Exercise Date). If any shares of Common Stock, Options or Common Stock Equivalents are issued or sold or deemed to have been issued or sold for cash, the consideration received therefor will be deemed to be the net amount of consideration received by the Company therefor. If any shares of Common Stock, Options or Common Stock Equivalents are issued or sold for a consideration other than cash, the amount of such consideration received by the Company will be the fair value of such consideration, except where such consideration consists of publicly traded securities, in which case the amount of consideration received by the Company for such securities will be the lowest VWAP on any Trading Day during the five (5) Trading Day period immediately preceding the date of receipt. If any shares of Common Stock, Options or Common Stock Equivalents are issued to the owners of the non-surviving entity in connection with any merger in which the Company is the surviving entity, the amount of consideration therefor will be deemed to be the fair value of such portion of the net assets and business of the non-surviving entity as is attributable to such shares of Common Stock, Options or Common Stock Equivalents (as the case may be). The fair value of any consideration other than cash or publicly traded securities will be reasonably determined jointly by the Company and the Holder.&nbsp; If such parties are unable to reach agreement within ten (10) days after the occurrence of an event requiring valuation (the &#8220;<u>Valuation Event</u>&#8221;), the fair value of such consideration will be determined within five (5) Trading Days after the tenth (10th) day following such Valuation Event by an independent, reputable appraiser jointly selected by the Company and the Holder.&nbsp; The determination of such appraiser shall be final and binding upon all parties absent manifest error and the fees and expenses of such appraiser shall be borne by the Company. For purposes of hereof, &#8220;<u>Adjustment Right</u>&#8221; means any right granted with respect to any securities issued in connection with, or with respect to, any issuance or sale (or deemed issuance or sale in accordance with this Section 3(e)) of shares of Common Stock (other than rights of the type described in Section 3(b) and Section 3(c) hereof) that could result in a decrease in the net consideration received by the Company in connection with, or with respect to, such securities (including, without limitation, any cash settlement rights, cash adjustment or other similar rights).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;text-indent:36pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Record Date</u>. If the Company takes a record of the holders of shares of Common Stock for the purpose of entitling them (A) to receive a dividend or other distribution payable in shares of Common Stock, Options or in Common Stock Equivalents or (B) to subscribe for or purchase shares of Common Stock, Options or Common Stock Equivalents, then such record date will be deemed to be the date of the issuance or sale of the shares of Common Stock deemed to have been issued or sold upon the declaration of such dividend or the making of such other distribution or the date of the granting of such right of subscription or purchase (as the case may be).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;text-indent:36pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Number of Warrant Shares</u>.&nbsp; Following the Authorized Share Increase Date, simultaneously with any adjustment to the Exercise Price pursuant to this Section&nbsp;3(e), the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the adjusted number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment (without regard to any limitations on exercise contained herein and the &#8220;aggregate Exercise Price&#8221; for purposes of the foregoing shall be the aggregate Exercise Price as of the Closing Date and may not be unilaterally reduced by the Company for any reason other than by exercise of this Warrant by the Holder). Notwithstanding the foregoing, in the event of any adjustment to the Exercise Price pursuant to this Section 3(e) that occurs prior to the Authorized Share Increase Date, on the Authorized Share Increase Date, the number of Warrant Shares shall be adjusted pursuant to this Section 3(e)(v) as if such adjustment to the Exercise Price occurred on the Authorized Share Increase Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">f)&nbsp;&nbsp;&nbsp;&nbsp;Reserved.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to Holder</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to Allow Exercise by Holder</u>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, as determined by the Company in consultation with Company Counsel, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Voluntary Adjustment By Company</u>. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of this Warrant, with the written consent of the Holder, reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Section 4</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer of Warrant</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transferability</u>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Section 5</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Miscellaneous</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="17" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorized Shares</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;text-indent:36pt;">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;text-indent:36pt;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="18" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;text-indent:36pt;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="19" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company, at 5300 Memorial Dr., Suite 950, Houston, Texas 77007, Attention:<b> </b>Jonathan P. Foster, email address: jfoster@moleculin.com and jsmith@moleculin.com, or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, as determined by the Company in consultation with Company Counsel, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">j)&nbsp;&nbsp;&nbsp;&nbsp;<u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">k)&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="20" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">20</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">l)&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder, on the other hand.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">m)&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">n)&nbsp;&nbsp;&nbsp;&nbsp;<u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">********************</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Signature Page Follows)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="21" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" valign="top" width="38%"><b>MOLECULIN BIOTECH, INC.</b></td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">Name:</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Title:</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="22" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">22</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTICE OF EXERCISE</b></p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">TO:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MOLECULIN BIOTECH, INC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Payment shall take the form of (check applicable box):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;">[ ] in lawful money of the United States; or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;">[ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[SIGNATURE OF HOLDER]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 8%; padding: 0px;">Name of Investing Entity:&nbsp;&nbsp;</td>
			<td style="width: 1685px; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 27%; padding: 0px;"><i>Signature of Authorized Signatory of Investing Entity</i>:&nbsp;&nbsp;</td>
			<td style="width: 1536px; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 17%; padding: 0px;">Name of Authorized Signatory:&nbsp;&nbsp;</td>
			<td style="width: 1617px; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 15%; padding: 0px;">Title of Authorized Signatory:&nbsp;&nbsp;</td>
			<td style="width: 1633px; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 1%; padding: 0px;">Date:&nbsp;&nbsp;</td>
			<td style="width: 1744px; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ASSIGNMENT FORM</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:11pt;"><i>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:11pt;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Name:</td>
			<td style="width: 33%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 27%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 33%;">(Please Print)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 27%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">Address:</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 33%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 27%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 33%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 27%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 33%;">(Please Print)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 27%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 33%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 27%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">Phone Number:</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 33%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 27%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 33%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 27%;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">Email Address:</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 33%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 27%;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td nowrap="true" style="width: 0%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">Dated:&nbsp; &nbsp;</td>
			<td style="width: 354px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">,</td>
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td nowrap="true" style="width: 7%; padding: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Holder&#8217;s Signature:&nbsp;&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); width: 568px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 60%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td nowrap="true" style="width: 5%; padding: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Holder&#8217;s Address:&nbsp;&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); width: 588px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 60%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>ex_901476.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<html><head>
	<title>ex_901476.htm</title>

	<!-- Generated by ThunderDome Portal - 12/21/2025 10:45:58 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 4.2</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>AMENDED AND RESTATED</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>SERIES F COMMON STOCK PURCHASE WARRANT</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>MOLECULIN BIOTECH, INC.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Warrant Shares: [_______]</td>
			<td style="width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&nbsp;</td>
			<td style="width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">New Issue Date: December __, 2025</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 33%; text-align: justify;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 33%; text-align: justify;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 33%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 33%; text-align: justify;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 33%; text-align: justify;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 33%; text-align: justify;">Original Issue Date: August 28, 2025</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">THIS AMENDED AND RESTATED SERIES F COMMON STOCK PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received, [_____________] or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholder Approval Date (the &#8220;<u>Initial Exercise Date</u>&#8221;) and on or prior to 5:00 p.m. (New York City time) on the five (5) year anniversary of the Initial Exercise Date, (the &#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase from Moleculin Biotech, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to [______] shares of Common Stock (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). The Company and the Holder each acknowledges and agrees that this Warrant amends and restates in its entirety and replaces that certain Series F Common Stock Purchase Warrant that was issued by the Company to the Holder on August 28, 2025, which is deemed cancelled as of the date hereof. Pursuant to Rule 144, the holding period of this Warrant and the Warrant Shares issuable upon exercise hereof shall tack back to August 28, 2025.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 1</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Affiliate</u>&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Board of Directors</u>&#8221; means the board of directors of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Business Day</u>&#8221; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; <u>provided</u>, <u>however</u>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#8220;stay at home&#8221;, &#8220;shelter-in-place&#8221;, &#8220;non-essential employee&#8221;&nbsp; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Commission</u>&#8221; means the United States Securities and Exchange Commission.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Common Stock</u>&#8221; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Common Stock Equivalents</u>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Floor Price</u>&#8221; means a price equal to $2.75, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the Issue Date.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Letter Agreement</u>&#8221; means the letter agreement, dated as of August 27, 2025 by and between the Company and the Holder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Person</u>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">&#8220;<u>Stockholder Approval</u>&#8221; means such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market (or any successor entity) from the stockholders of the Company with respect to issuance of all of the Warrants and the Warrant Shares upon the exercise thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">&#8220;<u>Stockholder Approval Date</u>&#8221; means the date on which Stockholder Approval is received and deemed effective under Delaware law.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Subsidiary</u>&#8221; means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Trading Day</u>&#8221; means a day on which the Common Stock is traded on a Trading Market.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Trading Market</u>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange (or any successors to any of the foregoing).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Transfer Agent</u>&#8221; means VStock Transfer, LLC, the current transfer agent of the Company, with a mailing address of 18 Lafayette Place, Woodmere, New York 11598 and an email address of info@vstocktransfer.com, and any successor transfer agent of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Warrants</u>&#8221; means this Warrant and other Amended and Restated Series F Common Stock purchase warrants issued by the Company on the date hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 2</u>.&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;<u>Exercise</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise on the Trading Day of receipt of such notice. <b>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise Price</u>. The exercise price per share of Common Stock under this Warrant shall be $3.90, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Cashless Exercise</u>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(A)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">= as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221;&nbsp;(as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;<u>Bloomberg</u>&#8221;) as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221;&nbsp;on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221;&nbsp;on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221;&nbsp;on such Trading Day;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(B)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">= the Exercise Price of this Warrant, as adjusted hereunder; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(X)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">= the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary to this Section 2(c).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">d)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Mechanics of Exercise</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">i.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221;&nbsp;means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 36pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 36pt; text-align: justify;">iii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 36pt; text-align: justify;">iv.&nbsp;&nbsp;&nbsp;&nbsp;<u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 36pt; text-align: justify;">v.&nbsp;&nbsp;&nbsp;&nbsp;<u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 36pt; text-align: justify;">vi.&nbsp;&nbsp;&nbsp;&nbsp;<u>Charges, Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 36pt; text-align: justify;">vii.&nbsp; &nbsp;&nbsp;<u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Holder&#8217;</u><u>s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<sup style="vertical-align:top;line-height:120%;">st</sup> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 3</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Adjustments</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Stock Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding Common Stock or greater than 50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires greater than 50% of the outstanding shares of Common Stock or greater than 50% of the voting power of the common equity of the Company (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; <u>provided</u>,<i> </i><u>however</u>, that, if the Fundamental Transaction is not approved by the Company's Board of Directors nor otherwise within the Company&#8217;s control, the Holder shall only be entitled to receive from the Company or any Successor Entity, as of the date of the consummation of such Fundamental Transaction, the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration (as considered by the Company&#8217;s Board of Directors) be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; <u>provided</u>, <u>further</u>, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &#8220;<u>Black Scholes Value</u>&#8221; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the "OV" function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction, or, if the Fundamental Transaction is not publicly announced, the date the Fundamental Transaction is consummated, for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of this Warrant as of such date of request, (ii) an expected volatility equal to the greater of (1) the 100 day volatility, as obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, and (2) 100%, (iii) the underlying price per share used in such calculation shall be the greater of (a) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (b) the higher of (1) the VWAP immediately preceding the public announcement of the applicable contemplated Fundamental Transaction and (2) the VWAP immediately preceding the consummation of the applicable Fundamental Transaction, (iv) a remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, and (v) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five Business Days of the Holder&#8217;s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &#8220;Company&#8221; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(d) regardless of (i) whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustment Upon Issuance of Shares of Common Stock</u>. If and whenever on or after the Issue Date, the Company issues or sells (or enters into any agreement to grant, issue or sell), or in accordance with this Section 3(e) is deemed to have issued or sold, any shares of Common Stock and/or Common Stock Equivalents (including the issuance or sale of shares of Common Stock owned or held by or for the account of the Company, but excluding any Exempt Issuance (as defined in the Letter Agreement)) for a consideration per share (the &#8220;<u>New Issuance Price</u>&#8221;) less than a price equal to the Exercise Price in effect immediately prior to such issuance or sale or deemed issuance or sale (such Exercise Price then in effect is referred to herein as the &#8220;<u>Applicable Price</u>&#8221;) (the foregoing a &#8220;<u>Dilutive Issuance</u>&#8221;), then simultaneously with the consummation (or, if earlier, the announcement) of each such Dilutive Issuance, the Exercise Price then in effect shall be reduced to an amount equal to the New Issuance Price; provided that the adjusted Exercise Price under this Section 3(e) shall not be less than the Floor Price. For all purposes of the foregoing (including, without limitation, determining the adjusted Exercise Price and the New Issuance Price under this Section 3(e)), the following shall be applicable:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">(i) <u>Issuance of Options</u>. If the Company in any manner grants or sells any rights, warrants or options to subscribe for or purchase shares of preferred stock and/or Common Stock or Common Stock Equivalents (&#8220;<u>Options</u>&#8221;) and the lowest price per share for which one share of Common Stock is at any time issuable upon the exercise of any such Option or upon conversion, exercise or exchange of any Common Stock Equivalents issuable upon exercise of any such Option or otherwise pursuant to the terms thereof is less than the Applicable Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the granting or sale of such Option for such price per share. For purposes of this Section 3(e)(i), the &#8220;lowest price per share for which one share of Common Stock is issuable upon the exercise of any such Options or upon conversion, exercise or exchange of any Common Stock Equivalents issuable upon exercise of any such Option or otherwise pursuant to the terms thereof&#8221; shall be equal to (1) the lower of (x) the sum of the lowest amounts of consideration (if any) received or receivable by the Company with respect to any one share of Common Stock upon the granting or sale of such Option, upon exercise of such Option and upon conversion, exercise or exchange of any Common Stock Equivalents issuable upon exercise of such Option or otherwise pursuant to the terms thereof and (y) the sum of the consideration received or receivable by the Company with respect to any one share of Common Stock upon the granting or sale of such Option and the lowest exercise price set forth in such Option for which one share of Common Stock is issuable upon the exercise of any such Options or upon conversion, exercise or exchange of any Common Stock Equivalents issuable upon exercise of any such Option or otherwise pursuant to the terms thereof minus (2) the sum of all amounts paid or payable to the holder of such Option (or any other Person) upon the granting, issuance or sale of such Option, upon exercise of such Option and upon conversion, exercise or exchange of any Common Stock Equivalents issuable upon exercise of such Option or otherwise pursuant to the terms thereof plus the value of any other consideration received or receivable by, or benefit conferred on, the holder of such Option (or any other Person). Except as contemplated below, no further adjustment of the Exercise Price shall be made upon the actual issuance of such shares of Common Stock or of such Common Stock Equivalents upon the exercise of such Options or otherwise pursuant to the terms of or upon the actual issuance of such shares of Common Stock upon conversion, exercise or exchange of such Common Stock Equivalents. This Section 3(e)(i) shall not apply to any Exempt Issuance.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">(ii)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Issuance of Common Stock Equivalents</u>. If the Company in any manner issues or sells any Common Stock Equivalents and the lowest price per share for which one share of Common Stock is at any time issuable upon the conversion, exercise or exchange thereof or otherwise pursuant to the terms thereof is less than the Exercise Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the issuance or sale of such Common Stock Equivalents for such price per share. For the purposes of this Section 3(e)(ii), the &#8220;lowest price per share for which one share of Common Stock is issuable upon the conversion, exercise or exchange thereof or otherwise pursuant to the terms thereof&#8221; shall be equal to (1) the lower of (x) the sum of the lowest amounts of consideration (if any) received or receivable by the Company with respect to one share of Common Stock upon the issuance or sale of the Common Stock Equivalent and upon conversion, exercise or exchange of such Common Stock Equivalent or otherwise pursuant to the terms thereof and (y) the sum of the consideration received or receivable by the Company with respect to any one share of Common Stock upon the granting or sale of such Common Stock Equivalent and the lowest conversion price set forth in such Common Stock Equivalent for which one share of Common Stock is issuable upon conversion, exercise or exchange thereof or otherwise pursuant to the terms thereof minus (2) the sum of all amounts paid or payable to the holder of such Common Stock Equivalent (or any other Person) upon the issuance or sale of such Common Stock Equivalent plus the value of any other consideration received or receivable by, or benefit conferred on, the holder of such Common Stock Equivalent (or any other Person). Except as contemplated below, no further adjustment of the Exercise Price shall be made upon the actual issuance of such shares of Common Stock upon conversion, exercise or exchange of such Common Stock Equivalents or otherwise pursuant to the terms thereof, and if any such issuance or sale of such Common Stock Equivalents is made upon exercise of any Options for which adjustment of the Warrant has been or is to be made pursuant to other provisions of this Section 3(e), except as contemplated below, no further adjustment of the Exercise Price shall be made by reason of such issuance or sale.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">(iii) <u>Reserved</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">(iv) <u>Calculation of Consideration Received</u>. If any Option and/or Common Stock Equivalent and/or Adjustment Right is issued in connection with the issuance or sale or deemed issuance or sale of any other securities of the Company (as reasonably determined jointly by the Holder and the Company, the &#8220;<u>Primary Security</u>&#8221; and such Option and/or Common Stock Equivalent and/or Adjustment Right, the &#8220;<u>Secondary Securities</u>&#8221; and, together with the Primary Security, each a &#8220;<u>Unit</u>&#8221;), together comprising one integrated transaction, the aggregate consideration per share of Common Stock with respect to such Primary Security shall be deemed to be the lowest of (x) the purchase price of such Unit, (y) if such Primary Security is an Option and/or Common Stock Equivalent, the lowest price per share for which one share of Common Stock is at any time issuable upon the exercise or conversion of the Primary Security in accordance with Section 3(e)(i) or 3(e)(ii) above and (z) the lowest VWAP on any Trading Day during the five (5) Trading Day period (the &#8220;<u>Adjustment Period</u>&#8221;) immediately following the public announcement of such Dilutive Issuance (for the avoidance of doubt, if such public announcement is released prior to the opening of the applicable Trading Market on a Trading Day, such Trading Day shall be the first Trading Day in such five Trading Day period and if this Warrant is exercised, on any given Exercise Date during any such Adjustment Period, solely with respect to such portion of this Warrant converted on such applicable Exercise Date, such applicable Adjustment Period shall be deemed to have ended on, and included, the Trading Day immediately prior to such Exercise Date). If any shares of Common Stock, Options or Common Stock Equivalents are issued or sold or deemed to have been issued or sold for cash, the consideration received therefor will be deemed to be the net amount of consideration received by the Company therefor. If any shares of Common Stock, Options or Common Stock Equivalents are issued or sold for a consideration other than cash, the amount of such consideration received by the Company will be the fair value of such consideration, except where such consideration consists of publicly traded securities, in which case the amount of consideration received by the Company for such securities will be the lowest VWAP on any Trading Day during the five (5) Trading Day period immediately preceding the date of receipt. If any shares of Common Stock, Options or Common Stock Equivalents are issued to the owners of the non-surviving entity in connection with any merger in which the Company is the surviving entity, the amount of consideration therefor will be deemed to be the fair value of such portion of the net assets and business of the non-surviving entity as is attributable to such shares of Common Stock, Options or Common Stock Equivalents (as the case may be). The fair value of any consideration other than cash or publicly traded securities will be reasonably determined jointly by the Company and the Holder.&nbsp; If such parties are unable to reach agreement within ten (10) days after the occurrence of an event requiring valuation (the &#8220;<u>Valuation Event</u>&#8221;), the fair value of such consideration will be determined within five (5) Trading Days after the tenth (10th) day following such Valuation Event by an independent, reputable appraiser jointly selected by the Company and the Holder.&nbsp; The determination of such appraiser shall be final and binding upon all parties absent manifest error and the fees and expenses of such appraiser shall be borne by the Company. For purposes of hereof, &#8220;<u>Adjustment Right</u>&#8221; means any right granted with respect to any securities issued in connection with, or with respect to, any issuance or sale (or deemed issuance or sale in accordance with this Section 3(e)) of shares of Common Stock (other than rights of the type described in Section 3(b) and Section 3(c) hereof) that could result in a decrease in the net consideration received by the Company in connection with, or with respect to, such securities (including, without limitation, any cash settlement rights, cash adjustment or other similar rights).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Record Date</u>. If the Company takes a record of the holders of shares of Common Stock for the purpose of entitling them (A) to receive a dividend or other distribution payable in shares of Common Stock, Options or in Common Stock Equivalents or (B) to subscribe for or purchase shares of Common Stock, Options or Common Stock Equivalents, then such record date will be deemed to be the date of the issuance or sale of the shares of Common Stock deemed to have been issued or sold upon the declaration of such dividend or the making of such other distribution or the date of the granting of such right of subscription or purchase (as the case may be).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Reserved</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to Holder</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to Allow Exercise by Holder</u>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, as determined by the Company in consultation with Company Counsel, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Voluntary Adjustment By Company</u>. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of this Warrant, with the written consent of the Holder, reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 4</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer of Warrant</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transferability</u>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and the Letter Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer Restrictions</u>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, provides to the Company an opinion of counsel, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that the transfer of this Warrant does not require registration under the Securities Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Representation by the Holder</u>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 5</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Miscellaneous</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorized Shares</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="17" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 18pt; text-align: justify;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="18" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company, at 5300 Memorial Dr., Suite 950, Houston, Texas 77007, Attention:<b> </b>Jonathan P. Foster, email address: jfoster@moleculin.com and jsmith@moleculin.com, or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, as determined by the Company in consultation with Company Counsel, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">j)&nbsp;&nbsp;&nbsp;&nbsp;<u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="19" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">k)&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">l)&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder, on the other hand.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">m)&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">n)&nbsp;&nbsp;&nbsp;&nbsp;<u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">********************</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><i>(Signature Page Follows)</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="20" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">20</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" valign="top" width="38%"><b>MOLECULIN BIOTECH, INC.</b></td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">Name: Jonathan P. Foster</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">Title: Chief Financial Officer</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="21" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>NOTICE OF EXERCISE</b></p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">TO:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MOLECULIN BIOTECH, INC.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(1)&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Payment shall take the form of (check applicable box):</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-align: justify;">[ ] in lawful money of the United States; or</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-align: justify;">[ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 47%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">(4) <u>Accredited Investor</u>. The undersigned is an &#8220;accredited investor&#8221; as defined in Regulation D promulgated under the Securities Act of 1933, as amended.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">[SIGNATURE OF HOLDER]</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 10%; padding: 0px;">Name of Investing Entity:&nbsp;&nbsp;</td>
			<td style="width: 1669px; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 21%; padding: 0px;"><i>Signature of Authorized Signatory of Investing Entity</i>:&nbsp;&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1581px;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 11%; padding: 0px;">Name of Authorized Signatory:&nbsp;&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1663px;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 13%; padding: 0px;">Title of Authorized Signatory:&nbsp;&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1649px;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td nowrap="true" style="width: 1%; padding: 0px;">Date:&nbsp;&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1742px;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: justify;">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>ASSIGNMENT FORM</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 11pt; text-align: justify;"><i>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 11pt; text-align: justify;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Name:</p>
			</td>
			<td style="vertical-align: middle; width: 33%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 27%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(Please Print)</p>
			</td>
			<td style="vertical-align: middle; width: 27%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Address:</p>
			</td>
			<td style="vertical-align: middle; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 27%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 33%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 27%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(Please Print)</p>
			</td>
			<td style="vertical-align: middle; width: 27%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 27%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Phone Number:</p>
			</td>
			<td style="vertical-align: middle; width: 33%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 27%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 27%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Email Address:</p>
			</td>
			<td style="vertical-align: middle; width: 33%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 27%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td nowrap="true" style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dated:&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 332px; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 2%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">,</p>
			</td>
			<td style="vertical-align: middle; width: 6%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td nowrap="true" style="vertical-align: middle; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Holder&#8217;s Signature:&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 594px; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 60%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td nowrap="true" style="vertical-align: middle; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Holder&#8217;s Address:&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 574px; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 60%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>ex_901551.htm
<DESCRIPTION>EXHIBIT 4.3
<TEXT>
<html><head>
	<title>ex_901551.htm</title>

	<!-- Generated by ThunderDome Portal - 12/22/2025 6:10:52 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 4.3</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AMENDED AND RESTATED</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SERIES G COMMON STOCK PURCHASE WARRANT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>MOLECULIN BIOTECH, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 70%;">Warrant Shares: [_______]</td>
			<td style="width: 30%;">New Issue Date: December __, 2025</td>
		</tr>
		<tr>
			<td style="width: 70%;">&nbsp;</td>
			<td style="width: 30%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 70%;">&nbsp;</td>
			<td style="width: 30%;">Original Issue Date: December 11, 2025</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">THIS AMENDED AND RESTATED SERIES G COMMON STOCK PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received, [_____________] or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholder Approval Date (the &#8220;<u>Initial Exercise Date</u>&#8221;) and on or prior to 5:00 p.m. (New York City time) on the five (5) year anniversary of the Initial Exercise Date, (the &#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase from Moleculin Biotech, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to [______] shares of Common Stock (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). The Company and the Holder each acknowledges and agrees that this Warrant amends and restates in its entirety and replaces that certain Series G Common Stock Purchase Warrant that was issued by the Company to the Holder on December 11, 2025, which is deemed cancelled as of the date hereof. Pursuant to Rule 144, the holding period of this Warrant and the Warrant Shares issuable upon exercise hereof shall tack back to December 11, 2025</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Section 1</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Affiliate</u>&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Board of Directors</u>&#8221; means the board of directors of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Business Day</u>&#8221; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; <u>provided</u>, <u>however</u>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#8220;stay at home&#8221;, &#8220;shelter-in-place&#8221;, &#8220;non-essential employee&#8221;&nbsp; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Commission</u>&#8221; means the United States Securities and Exchange Commission.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Common Stock</u>&#8221; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Common Stock Equivalents</u>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Floor Price</u>&#8221; means a price equal to $1.326, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the Issue Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Letter Agreement</u>&#8221; means the letter agreement, dated as of December 9, 2025 by and between the Company and the Holder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Person</u>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">&#8220;<u>Stockholder Approval</u>&#8221; means such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market (or any successor entity) from the stockholders of the Company with respect to issuance of all of the Warrants and the Warrant Shares upon the exercise thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">&#8220;<u>Stockholder Approval Date</u>&#8221; means the date on which Stockholder Approval is received and deemed effective under Delaware law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Subsidiary</u>&#8221; means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Trading Day</u>&#8221; means a day on which the Common Stock is traded on a Trading Market.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Trading Market</u>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange (or any successors to any of the foregoing).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Transfer Agent</u>&#8221; means VStock Transfer, LLC, the current transfer agent of the Company, with a mailing address of 18 Lafayette Place, Woodmere, New York 11598 and an email address of info@vstocktransfer.com, and any successor transfer agent of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;<u>Warrants</u>&#8221; means this Warrant and other Amended and Restated Series G Common Stock purchase warrants issued by the Company on the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 2</u>.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Exercise</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise on the Trading Day of receipt of such notice. <b>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp; &nbsp; &nbsp; &nbsp;<u>Exercise Price</u>. The exercise price per share of Common Stock under this Warrant shall be $3.90, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp; &nbsp; &nbsp; &nbsp;<u>Cashless Exercise</u>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 75pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(A)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">= as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221;&nbsp;(as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;<u>Bloomberg</u>&#8221;) as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221;&nbsp;on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221;&nbsp;on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221;&nbsp;on such Trading Day;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 75pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 75pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">(B)</td>
			<td style="vertical-align: top; text-align: justify;">= the Exercise Price of this Warrant, as adjusted hereunder; and</td>
		</tr>
		<tr>
			<td style="width: 75pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 75pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">(X)</td>
			<td style="vertical-align: top; text-align: justify; padding-left: 9pt; text-indent: -9pt;">= the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary to this Section 2(c).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">d)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Mechanics of Exercise</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">i.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221;&nbsp;means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">iii.&nbsp; &nbsp;<u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">iv.&nbsp;&nbsp;&nbsp;&nbsp;<u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">v.&nbsp;&nbsp;&nbsp;&nbsp;<u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">vi.&nbsp;&nbsp;&nbsp;&nbsp;<u>Charges, Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">vii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp; &nbsp; &nbsp; &nbsp;<u>Holder</u><u>&#8217;</u><u>s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<sup style="vertical-align:top;line-height:120%;">st</sup> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 3</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Adjustments</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">a)&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Stock Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">b)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">c)&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">d)&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding Common Stock or greater than 50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires greater than 50% of the outstanding shares of Common Stock or greater than 50% of the voting power of the common equity of the Company (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; <u>provided</u>,<i> </i><u>however</u>, that, if the Fundamental Transaction is not approved by the Company's Board of Directors nor otherwise within the Company&#8217;s control, the Holder shall only be entitled to receive from the Company or any Successor Entity, as of the date of the consummation of such Fundamental Transaction, the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration (as considered by the Company&#8217;s Board of Directors) be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; <u>provided</u>, <u>further</u>, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &#8220;<u>Black Scholes Value</u>&#8221; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the "OV" function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction, or, if the Fundamental Transaction is not publicly announced, the date the Fundamental Transaction is consummated, for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of this Warrant as of such date of request, (ii) an expected volatility equal to the greater of (1) the 100 day volatility, as obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, and (2) 100%, (iii) the underlying price per share used in such calculation shall be the greater of (a) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (b) the higher of (1) the VWAP immediately preceding the public announcement of the applicable contemplated Fundamental Transaction and (2) the VWAP immediately preceding the consummation of the applicable Fundamental Transaction, (iv) a remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, and (v) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five Business Days of the Holder&#8217;s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &#8220;Company&#8221; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(d) regardless of (i) whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">e)&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Adjustment Upon Issuance of Shares of Common Stock</u>. If and whenever on or after the Issue Date, the Company issues or sells (or enters into any agreement to grant, issue or sell), or in accordance with this Section 3(e) is deemed to have issued or sold, any shares of Common Stock and/or Common Stock Equivalents (including the issuance or sale of shares of Common Stock owned or held by or for the account of the Company, but excluding any Exempt Issuance (as defined in the Letter Agreement)) for a consideration per share (the &#8220;<u>New Issuance Price</u>&#8221;) less than a price equal to the Exercise Price in effect immediately prior to such issuance or sale or deemed issuance or sale (such Exercise Price then in effect is referred to herein as the &#8220;<u>Applicable Price</u>&#8221;) (the foregoing a &#8220;<u>Dilutive Issuance</u>&#8221;), then simultaneously with the consummation (or, if earlier, the announcement) of each such Dilutive Issuance, the Exercise Price then in effect shall be reduced to an amount equal to the New Issuance Price; provided that the adjusted Exercise Price under this Section 3(e) shall not be less than the Floor Price. For all purposes of the foregoing (including, without limitation, determining the adjusted Exercise Price and the New Issuance Price under this Section 3(e)), the following shall be applicable:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 36pt; text-align: justify;">(i)&nbsp; &nbsp;&nbsp;<u>Issuance of Options</u>. If the Company in any manner grants or sells any rights, warrants or options to subscribe for or purchase shares of preferred stock and/or Common Stock or Common Stock Equivalents (&#8220;<u>Options</u>&#8221;) and the lowest price per share for which one share of Common Stock is at any time issuable upon the exercise of any such Option or upon conversion, exercise or exchange of any Common Stock Equivalents issuable upon exercise of any such Option or otherwise pursuant to the terms thereof is less than the Applicable Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the granting or sale of such Option for such price per share. For purposes of this Section 3(e)(i), the &#8220;lowest price per share for which one share of Common Stock is issuable upon the exercise of any such Options or upon conversion, exercise or exchange of any Common Stock Equivalents issuable upon exercise of any such Option or otherwise pursuant to the terms thereof&#8221; shall be equal to (1) the lower of (x) the sum of the lowest amounts of consideration (if any) received or receivable by the Company with respect to any one share of Common Stock upon the granting or sale of such Option, upon exercise of such Option and upon conversion, exercise or exchange of any Common Stock Equivalents issuable upon exercise of such Option or otherwise pursuant to the terms thereof and (y) the sum of the consideration received or receivable by the Company with respect to any one share of Common Stock upon the granting or sale of such Option and the lowest exercise price set forth in such Option for which one share of Common Stock is issuable upon the exercise of any such Options or upon conversion, exercise or exchange of any Common Stock Equivalents issuable upon exercise of any such Option or otherwise pursuant to the terms thereof minus (2) the sum of all amounts paid or payable to the holder of such Option (or any other Person) upon the granting, issuance or sale of such Option, upon exercise of such Option and upon conversion, exercise or exchange of any Common Stock Equivalents issuable upon exercise of such Option or otherwise pursuant to the terms thereof plus the value of any other consideration received or receivable by, or benefit conferred on, the holder of such Option (or any other Person). Except as contemplated below, no further adjustment of the Exercise Price shall be made upon the actual issuance of such shares of Common Stock or of such Common Stock Equivalents upon the exercise of such Options or otherwise pursuant to the terms of or upon the actual issuance of such shares of Common Stock upon conversion, exercise or exchange of such Common Stock Equivalents. This Section 3(e)(i) shall not apply to any Exempt Issuance.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 9pt; text-align: justify;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp; &nbsp;&nbsp;<u>Issuance of Common Stock Equivalents</u>. If the Company in any manner issues or sells any Common Stock Equivalents and the lowest price per share for which one share of Common Stock is at any time issuable upon the conversion, exercise or exchange thereof or otherwise pursuant to the terms thereof is less than the Exercise Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the issuance or sale of such Common Stock Equivalents for such price per share. For the purposes of this Section 3(e)(ii), the &#8220;lowest price per share for which one share of Common Stock is issuable upon the conversion, exercise or exchange thereof or otherwise pursuant to the terms thereof&#8221; shall be equal to (1) the lower of (x) the sum of the lowest amounts of consideration (if any) received or receivable by the Company with respect to one share of Common Stock upon the issuance or sale of the Common Stock Equivalent and upon conversion, exercise or exchange of such Common Stock Equivalent or otherwise pursuant to the terms thereof and (y) the sum of the consideration received or receivable by the Company with respect to any one share of Common Stock upon the granting or sale of such Common Stock Equivalent and the lowest conversion price set forth in such Common Stock Equivalent for which one share of Common Stock is issuable upon conversion, exercise or exchange thereof or otherwise pursuant to the terms thereof minus (2) the sum of all amounts paid or payable to the holder of such Common Stock Equivalent (or any other Person) upon the issuance or sale of such Common Stock Equivalent plus the value of any other consideration received or receivable by, or benefit conferred on, the holder of such Common Stock Equivalent (or any other Person). Except as contemplated below, no further adjustment of the Exercise Price shall be made upon the actual issuance of such shares of Common Stock upon conversion, exercise or exchange of such Common Stock Equivalents or otherwise pursuant to the terms thereof, and if any such issuance or sale of such Common Stock Equivalents is made upon exercise of any Options for which adjustment of the Warrant has been or is to be made pursuant to other provisions of this Section 3(e), except as contemplated below, no further adjustment of the Exercise Price shall be made by reason of such issuance or sale.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 36pt; text-align: justify;">(iii)&nbsp; &nbsp;<u>Reserved</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 36pt; text-align: justify;">(iv)&nbsp;&nbsp;<u>Calculation of Consideration Received</u>. If any Option and/or Common Stock Equivalent and/or Adjustment Right is issued in connection with the issuance or sale or deemed issuance or sale of any other securities of the Company (as reasonably determined jointly by the Holder and the Company, the &#8220;<u>Primary Security</u>&#8221; and such Option and/or Common Stock Equivalent and/or Adjustment Right, the &#8220;<u>Secondary Securities</u>&#8221; and, together with the Primary Security, each a &#8220;<u>Unit</u>&#8221;), together comprising one integrated transaction, the aggregate consideration per share of Common Stock with respect to such Primary Security shall be deemed to be the lowest of (x) the purchase price of such Unit, (y) if such Primary Security is an Option and/or Common Stock Equivalent, the lowest price per share for which one share of Common Stock is at any time issuable upon the exercise or conversion of the Primary Security in accordance with Section 3(e)(i) or 3(e)(ii) above and (z) the lowest VWAP on any Trading Day during the five (5) Trading Day period (the &#8220;<u>Adjustment Period</u>&#8221;) immediately following the public announcement of such Dilutive Issuance (for the avoidance of doubt, if such public announcement is released prior to the opening of the applicable Trading Market on a Trading Day, such Trading Day shall be the first Trading Day in such five Trading Day period and if this Warrant is exercised, on any given Exercise Date during any such Adjustment Period, solely with respect to such portion of this Warrant converted on such applicable Exercise Date, such applicable Adjustment Period shall be deemed to have ended on, and included, the Trading Day immediately prior to such Exercise Date). If any shares of Common Stock, Options or Common Stock Equivalents are issued or sold or deemed to have been issued or sold for cash, the consideration received therefor will be deemed to be the net amount of consideration received by the Company therefor. If any shares of Common Stock, Options or Common Stock Equivalents are issued or sold for a consideration other than cash, the amount of such consideration received by the Company will be the fair value of such consideration, except where such consideration consists of publicly traded securities, in which case the amount of consideration received by the Company for such securities will be the lowest VWAP on any Trading Day during the five (5) Trading Day period immediately preceding the date of receipt. If any shares of Common Stock, Options or Common Stock Equivalents are issued to the owners of the non-surviving entity in connection with any merger in which the Company is the surviving entity, the amount of consideration therefor will be deemed to be the fair value of such portion of the net assets and business of the non-surviving entity as is attributable to such shares of Common Stock, Options or Common Stock Equivalents (as the case may be). The fair value of any consideration other than cash or publicly traded securities will be reasonably determined jointly by the Company and the Holder.&nbsp; If such parties are unable to reach agreement within ten (10) days after the occurrence of an event requiring valuation (the &#8220;<u>Valuation Event</u>&#8221;), the fair value of such consideration will be determined within five (5) Trading Days after the tenth (10th) day following such Valuation Event by an independent, reputable appraiser jointly selected by the Company and the Holder.&nbsp; The determination of such appraiser shall be final and binding upon all parties absent manifest error and the fees and expenses of such appraiser shall be borne by the Company. For purposes of hereof, &#8220;<u>Adjustment Right</u>&#8221; means any right granted with respect to any securities issued in connection with, or with respect to, any issuance or sale (or deemed issuance or sale in accordance with this Section 3(e)) of shares of Common Stock (other than rights of the type described in Section 3(b) and Section 3(c) hereof) that could result in a decrease in the net consideration received by the Company in connection with, or with respect to, such securities (including, without limitation, any cash settlement rights, cash adjustment or other similar rights).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 90pt; text-indent: 36pt; text-align: justify;">(iv)&nbsp;&nbsp;&nbsp;<u>Record Date</u>. If the Company takes a record of the holders of shares of Common Stock for the purpose of entitling them (A) to receive a dividend or other distribution payable in shares of Common Stock, Options or in Common Stock Equivalents or (B) to subscribe for or purchase shares of Common Stock, Options or Common Stock Equivalents, then such record date will be deemed to be the date of the issuance or sale of the shares of Common Stock deemed to have been issued or sold upon the declaration of such dividend or the making of such other distribution or the date of the granting of such right of subscription or purchase (as the case may be).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">f)&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Reserved</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">g)&nbsp; &nbsp; &nbsp; &nbsp;<u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">h)&nbsp; &nbsp; &nbsp; &nbsp;<u>Notice to Holder</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 27pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to Allow Exercise by Holder</u>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, as determined by the Company in consultation with Company Counsel, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">i)&nbsp; &nbsp; &nbsp; &nbsp;<u>Voluntary Adjustment By Company</u>. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of this Warrant, with the written consent of the Holder, reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 4</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer of Warrant</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp; &nbsp; &nbsp;&nbsp;<u>Transferability</u>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and the Letter Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp; &nbsp; &nbsp;<u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp; &nbsp; &nbsp;<u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp; &nbsp; &nbsp;&nbsp;<u>Transfer Restrictions</u>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, provides to the Company an opinion of counsel, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that the transfer of this Warrant does not require registration under the Securities Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Representation by the Holder</u>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 5</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Miscellaneous</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp; &nbsp; &nbsp; <u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp; &nbsp; &nbsp;&nbsp;<u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp; &nbsp;&nbsp;<u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Authorized Shares</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 27pt; text-align: justify;">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="17" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 27pt; text-align: justify;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 27pt; text-align: justify;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp; &nbsp; &nbsp; &nbsp;<u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">f)&nbsp; &nbsp; &nbsp;&nbsp;<u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="18" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">g)&nbsp; &nbsp;&nbsp; &nbsp;<u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">h)&nbsp; &nbsp; &nbsp;<u>Notices</u>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company, at 5300 Memorial Dr., Suite 950, Houston, Texas 77007, Attention:<b> </b>Jonathan P. Foster, email address: jfoster@moleculin.com and jsmith@moleculin.com, or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, as determined by the Company in consultation with Company Counsel, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">i)&nbsp; &nbsp; &nbsp; &nbsp;<u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">j)&nbsp; &nbsp; &nbsp; &nbsp;<u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="19" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">k)&nbsp; &nbsp; &nbsp; &nbsp;<u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">l)&nbsp; &nbsp; &nbsp; &nbsp;<u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder, on the other hand.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">m)&nbsp; &nbsp; &nbsp;<u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">n)&nbsp; &nbsp; &nbsp; &nbsp;<u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">********************</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><i>(Signature Page Follows)</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="20" data-prefix="" data-suffix="" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">20</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="width: 100%; text-align: justify;">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-indent: 0px; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif;">

		<tr>
			<td style="width: 45%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-size: 10pt;">&nbsp;</font></p>
			</td>
			<td colspan="2" style="width: 3%;" valign="top" width="38%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>MOLECULIN BIOTECH, INC.</b></p>
			</td>
			<td style="width: 7%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-size: 10pt;">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-size: 10pt;">&nbsp;</font></p>
			</td>
			<td style="width: 3%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-size: 10pt;">&nbsp;</font></p>
			</td>
			<td style="width: 45%;" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-size: 10pt;">&nbsp;</font></p>
			</td>
			<td style="width: 7%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-size: 10pt;">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-size: 10pt;">&nbsp;</font></p>
			</td>
			<td style="width: 3%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-size: 10pt;">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" style="width: 45%;" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-size: 10pt;">&nbsp;</font></p>
			</td>
			<td style="width: 7%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-size: 10pt;">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="width: 45%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-size: 10pt;">&nbsp;</font></p>
			</td>
			<td style="width: 3%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-size: 10pt;">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="width: 45%; border-bottom: 1px solid black;" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>
			</td>
			<td style="width: 7%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-size: 10pt;">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-size: 10pt;">&nbsp;</font></p>
			</td>
			<td style="width: 3%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-size: 10pt;">&nbsp;</font></p>
			</td>
			<td style="width: 45%;" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Name: Jonathan P. Foster</p>
			</td>
			<td style="width: 7%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-size: 10pt;">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-size: 10pt;">&nbsp;</font></p>
			</td>
			<td style="width: 3%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-size: 10pt;">&nbsp;</font></p>
			</td>
			<td style="width: 45%;" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Title: Chief Financial Officer</p>
			</td>
			<td style="width: 7%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-size: 10pt;">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="21" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>NOTICE OF EXERCISE</b></p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">TO:</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">MOLECULIN BIOTECH, INC.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(1)&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Payment shall take the form of (check applicable box):</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-align: justify;">[ ] in lawful money of the United States; or</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-align: justify;">[ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-align: justify;">_______________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-align: justify;">_______________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-align: justify;">_______________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-align: justify;">_______________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">(4)&nbsp; &nbsp;<u>Accredited Investor</u>. The undersigned is an &#8220;accredited investor&#8221; as defined in Regulation D promulgated under the Securities Act of 1933, as amended.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">[SIGNATURE OF HOLDER]</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 20%;">Name of Investing Entity:</td>
			<td style="width: 80%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 37%;"><i>Signature of Authorized Signatory of Investing Entity</i>:</td>
			<td style="width: 63%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 22%;">Name of Authorized Signatory:</td>
			<td style="width: 78%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 22%;">Title of Authorized Signatory:</td>
			<td style="width: 78%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 5%;">Date:</td>
			<td style="width: 95%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="width: 100%; text-align: justify;">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="width: 100%; text-align: justify;">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>ASSIGNMENT FORM</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 11pt; text-align: justify;"><i>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 11pt; text-align: justify;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Name:</p>
			</td>
			<td style="vertical-align: top; width: 40%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 14%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 46%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(Please Print)</p>
			</td>
			<td style="vertical-align: top; width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Address:</p>
			</td>
			<td style="vertical-align: top; width: 40%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 14%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(Please Print)</td>
			<td style="vertical-align: top; width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Phone Number:</p>
			</td>
			<td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Email Address:</td>
			<td style="vertical-align: top; width: 40%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 14%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Dated: _______________ __, ______</p>
			</td>
			<td style="vertical-align: top; width: 40%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Holder&#8217;s Signature:<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></p>
			</td>
			<td style="vertical-align: top; width: 40%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 40%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Holder&#8217;s Address:<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></p>
			</td>
			<td style="vertical-align: top; width: 40%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>ex_901477.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html><head>
	<title>ex_901477.htm</title>

	<!-- Generated by ThunderDome Portal - 12/22/2025 4:06:18 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>MOLECULIN BIOTECH, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">December 21, 2025</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Holder of Common Stock Purchase Warrants</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Re:</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Offer to Amend Common Stock Purchase Warrants</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Dear Holder:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Moleculin Biotech, Inc. (the &#8220;<u>Company</u>&#8221;) is pleased to offer to you the opportunity to amend the Series E warrants (the &#8220;<u>Series E Warrants</u>&#8221;) to purchase shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;<u>Common Stock</u>&#8221;) and the Series F Common Stock purchase warrants (the &#8220;<u>Series F Warrants</u>&#8221; and together with the Series E Warrants, the &#8220;<u>Existing Warrants</u>&#8221;) and currently held by you (the &#8220;<u>Holder</u>&#8221;). Capitalized terms not otherwise defined herein shall have the meanings set forth in the Existing Warrants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Holder hereby agrees to amend the Existing Warrants as follows and, in consideration for such amendments, the Company also agrees to the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Pursuant to Section 3(i) of the Series F Warrants, the Company and the Holder hereby agree to reduce the Exercise Price of the Series F Warrant to equal $3.90, subject to adjustment therein. As such, Section 2(b) of the Series F Warrants is hereby amended and restated in its entirety as follows:</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;<u>Exercise Price</u></i><i>. The exercise price per share of Common Stock under this Warrant shall be $3.90, subject to adjustment hereunder (the </i>&#8220;<i><u>Exercise Price</u></i>&#8221;<i>).</i>&#8221;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company acknowledges and agrees that upon the adjustment of the Exercise Price of the Series F Warrants, that, pursuant to the terms and conditions of Section 3(e)(iii) and (v) of the Series E Warrants, the Exercise Price of the Series E Warrants shall be reduced to $3.90, subject to adjustment therein, and the number of Warrant Shares issuable upon exercise of the Series E Warrants shall increase accordingly. Such adjustment to the Exercise Price and the number of Warrant Shares in the Series E Warrants shall occur prior to the amendment to Section 3(e)(iii) set forth below.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt; text-align: justify;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Clause (ii) of the definition of Black Scholes Value in Section 3(d) of the Existing Warrants is hereby amended and restated as follows:</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;(ii) an expected volatility equal to the greater of (1) the 100 day volatility as obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, and (2) 100%</i>&#8221;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 3(e)(iii) of the Existing Warrants is amended to delete the clause in its entirety.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 3(f) of the Existing Warrants is amended to delete the clause in its entirety.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Holder may accept this offer by signing this letter below, with such acceptance constituting Holder's amendment of the Existing Warrants on or before 7:00 a.m., Eastern Time, on December 22, 2025 (the &#8220;<u>Execution Time</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Upon the acceptance of this letter agreement, from the date hereof until the 6 month anniversary of the date hereof, neither the Company nor any Subsidiary shall (A) reduce the exercise price of any existing Common Stock purchase warrants and (B) undertake a reverse or forward stock split or reclassification of the Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">If this offer is accepted and the transaction documents are executed by the Execution Time, then the Company shall deliver amended and restated Series E Warrants, Series F Warrants and Series G Warrants, in the forms of Exhibit A-1, Exhibit A-2 and Exhibit A-3 attached hereto, no later than the second (2<sup style="vertical-align:top;line-height:120%;">nd</sup>) Trading Day following the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Additionally, the Company agrees to the representations and warranties set forth on&nbsp;<u>Annex A</u>&nbsp;attached hereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">If this offer is accepted and the transaction documents are executed by the Execution Time, then on or before 8:00 a.m., Eastern Time, on the Trading Day following the date hereof, the Company shall file a Current Report on Form 8-K with the Commission disclosing all material terms of the transactions contemplated hereunder. From and after the filing of such Current Report on Form 8-K the Company represents to you that it shall have publicly disclosed all material, non-public information delivered to you by the Company, or any of its respective officers, directors, employees or agents in connection with the transactions contemplated hereunder. In addition, effective upon the filing of such Current Report on Form 8-K, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates on the one hand, and you and your Affiliates on the other hand, shall terminate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company acknowledges and agrees that the obligations of the Holder under this letter agreement are several and not joint with the obligations of any other holder or holders of Existing Warrants or other warrants of the Company (each, an &#8220;<u>Other Holder</u>&#8221;) under any other agreement related to the amendment of such warrants (&#8220;<u>Other Amendment Agreement(s)</u>&#8221;), and the Holder shall not be responsible in any way for the performance of the obligations of any Other Holder or under any such Other Amendment Agreement. Nothing contained in this letter agreement, and no action taken by the Holder pursuant hereto, shall be deemed to constitute the Holder and the Other Holders as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Holder and the Other Holders are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by this letter agreement and the Company acknowledges that the Holder and the Other Holders are not acting in concert or as a group with respect to such obligations or the transactions contemplated by this letter agreement or any Other Amendment Agreement. The Company and the Holder confirm that the Holder has independently participated in the negotiation of the transactions contemplated hereby with the advice of its own counsel and advisors. The Holder shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this letter agreement, and it shall not be necessary for any Other Holder to be joined as an additional party in any proceeding for such purpose.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">If you, the Holder, were a holder pursuant to that certain Warrant Inducement Letter Agreement, dated December 9, 2025, by and between the Company and the holders signatory thereto (the &#8220;<u>2025 Letter Agreement</u>&#8221;), you hereby agree to waive the Company prohibition on subsequent equity sales pursuant to Section (h) of Annex A of the 2025 Letter Agreement, as applicable, solely with respect to the reduction in the Exercise Price of the Existing Warrants. As partial consideration for this waiver, the Company irrevocably agrees to reduce the Exercise Price of the Series G Common Stock purchase warrants (the &#8220;<u>Series G Warrants</u>&#8221;) to equal $3.90, subject to adjustment therein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">***************</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" style="width: 3%;" valign="top" width="38%">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Sincerely yours,</p>

			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>MOLECULIN BIOTECH, INC.</b></p>
			</td>
			<td style="width: 20%;" valign="top" width="12%">
			<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 3%;" valign="top" width="3%">
			<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 27%;" valign="top" width="35%">
			<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 20%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 3%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" style="width: 27%;" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 20%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left; width: 50%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left; width: 3%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="border-bottom: 1px solid rgb(0, 0, 0); width: 27%;" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>
			</td>
			<td style="width: 20%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" rowspan="1" style="width: 3%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Name:</p>
			</td>
			<td style="width: 20%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" rowspan="1" style="width: 3%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Title:</p>
			</td>
			<td style="width: 20%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;&nbsp;&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Accepted and Agreed to:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name of Holder: ________________________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Signature of Authorized Signatory of Holder</i>: _________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name of Authorized Signatory: _______________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Title of Authorized Signatory: ________________________________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">[<i>Holder Signature Page to MBRX Warrant Amendment Letter</i>]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Annex A</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><u>Representations, Warranties and Covenants of the Company</u>. The Company hereby makes the following representations and warranties to the Holder:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorization; Enforcement</u>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this letter agreement and otherwise to carry out its obligations hereunder. The execution and delivery of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, its board of directors or its stockholders in connection herewith. This letter agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">b)&nbsp; &nbsp; <u>No Conflicts</u>. The execution, delivery and performance of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company&#8217;s certificate or articles of incorporation, bylaws or other organizational or charter documents; or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any &nbsp;liens, claims, security interests, other encumbrances or defects upon any of the properties or assets of the Company in connection with, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement, credit facility, debt or other material instrument (evidencing Company debt or otherwise) or other material understanding to which such Company is a party or by which any property or asset of the Company is bound or affected; or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected, except, in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a material adverse effect upon the business, prospects, properties, operations, condition (financial or otherwise) or results of operations of the Company, taken as a whole, or in its ability to perform its obligations under this letter agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp; &nbsp;&nbsp;<u>Filings, Consents and Approvals</u>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of this letter agreement, other than: (i) the filings required pursuant to this letter agreement, (ii) the filing of Form D with the Commission, (iii) Stockholder Approval (as defined in the Series G Warrants) for the Series G Warrants, and (iv) such filings as are required to be made under applicable state securities laws</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">d)&nbsp; &nbsp;&nbsp;&nbsp;<u>Trading Market</u>. The transactions contemplated under this letter agreement comply with all the rules and regulations of the Nasdaq Capital Market.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>mbrx-20251221.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 12/22/2025 1:12:32 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:mbrx="http://www.mbrx.com/20251221" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.mbrx.com/20251221">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/cyd-8k-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-8k-sub-2024.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20251221_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20251221_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20251221_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.mbrx.com/20251221/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="mbrx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>mbrx-20251221_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 12/22/2025 1:12:33 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.mbrx.com/20251221/role/statement-document-and-entity-information" xlink:href="mbrx-20251221.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.mbrx.com/20251221/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>mbrx-20251221_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 12/22/2025 1:12:32 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>mbrx-20251221_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 12/22/2025 1:12:33 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.mbrx.com/20251221/role/statement-document-and-entity-information" xlink:href="mbrx-20251221.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.mbrx.com/20251221/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>logosm01.jpg
<TEXT>
begin 644 logosm01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!P17AI9@  34T *@    @ !@$Q  (
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.444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 21, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">MOLECULIN BIOTECH, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Dec. 21,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-37758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">47-4671997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">5300 Memorial Drive, Suite 950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">77007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">300-5160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MBRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001659617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mbrx20251221_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mbrx.com/20251221/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mbrx-20251221.xsd</File>
    <File>mbrx-20251221_def.xml</File>
    <File>mbrx-20251221_lab.xml</File>
    <File>mbrx-20251221_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="mbrx20251221_8k.htm">mbrx20251221_8k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>logosm01.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mbrx20251221_8k.htm": {
   "nsprefix": "mbrx",
   "nsuri": "http://www.mbrx.com/20251221",
   "dts": {
    "schema": {
     "local": [
      "mbrx-20251221.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-8k-sub-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-cr-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "mbrx-20251221_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "mbrx-20251221_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mbrx-20251221_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "mbrx20251221_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 36,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.mbrx.com/20251221/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d20258K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mbrx20251221_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d20258K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mbrx20251221_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "cyd_MaterialCybersecurityIncidentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAxis",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Axis]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "cyd_MaterialCybersecurityIncidentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentDomain",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Domain]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r8"
     ]
    },
    "cyd_MaterialCybersecurityIncidentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Table]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.mbrx.com/20251221/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001437749-25-038478-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-25-038478-xbrl.zip
M4$L#!!0    ( /E&EEO&Q\I0;58  *@I @ -    97A?.3 Q-#<U+FAT;>U]
M>7?;2';OWS.? L^9).([D%J+W5[;)[*MGG;B[5GJ[N3,R9D#$B"%-@AP % R
MY]._N]6* A=+MF2;?9*Q38*HJEM5=_G=[<EY.RV>/CG/DO3IG__TI,W;(GN:
M??S[P_V#N_?O[<&W3W[@#__\)_C^_^SN1G_-RJQ.VBR-AHOH['Q>IEG]HIIF
MT;NJ;I,BVHT.#G\X//CA</_P7G2P_^CNW4='#Z)WKZ/=W:=/IEF;1*/SI&ZR
M]J<[\W:\^^".?%HFT^RG.^.JGB;M;IJUV:C-J_).-*K*-BOAZ38KLMEY568_
ME=6=IW]^\@//^LFP2A=1TRX*^GG9[C;Y/[-',/2L?1S1!^-DFA>+1]&__6->
MM8_/\FG61&^RR^A]-4U*_O!Q-$O2-"\GCZ+]O(SV]P[R\G$TFM=-53^*DGE;
M/<8QT_Q"32A+\S89TJ!)T61WHC1ID]UD-BL6;06S51_ 3W=GDW(^_>E.TR:U
M^CS-FUF1+.CS _D,)\MD\.9H?8^+@U_ XN1#>(,L/I%/9G4VSC_^=$?^2:,Z
MXS3SL?U FWV$C<LGY4]W1KBP^L[3?RN'S>SQDQ]@O4___.<G,T7?:5)/\A)H
M-/L8$7WQM[OTXT=1G4_.%<D_:0_@*."SSF:JW_V[]Y-_CR/Z)(Z:K,['G6'A
M7<.G)Q_/\V'>1G?W#I[\,'SZY =\"/Z8K;^H(AO?HC6I?0FNPWYWY]6/S;MH
M!?3/BZ3.D[)]5.*M*QX+(?!K(D$.=QN^/=A_ )^8P3_?J.N,X0VQS@C6?O(!
M=\>$@W+\^N3-BY,7T?&;%]'[D].SXS/XQ^G)^Y<GI]%)]/SMZ]=OWT2G9V^?
M_U?T[M?WSW\Y/CV)?C]^__[XS1D?K&^0)J_?OCIY_NNKEV^B9R_?GIT\_R6.
M7KYYOK=JO=<_%V?]Q'.C4584PK!_ND.\$#]I9LG(?')5D>!?QLL\;<_Q)?O_
M^CCB">XB=WC$3$,^(2;(']TAH0E2M0[>_@V&]M> ;\87I^K%,K>CHW_]]/5U
M!_D]J6O8IN@4!';6/(K^]G?^[W_5CK3IEYG(EQX/?_"R:>99] (TG4?1BVR4
M38=9'?W][W&$BHV:"OQ9/_U">WQ=+XXLFBTC[;<XWG:_;OMX;X&!YB78$?;]
M^\]YF46'1\&[!X8 R83K%$B?7_QN.,)RTR4LXM2(D0SIJ+5_S)LV'R^4V'ID
M*;ZB]47W#VER9[^\/(VNH!]%.^UY%OW;OSPX/-Q__&2NA,J3'^9/Z<.#QP,0
MWC7,)H>UM>=)&\/\Z^@B*6#_:^"\^466QEKXB B*X)&\;:*D:6!!C3_*+U4!
M=JDS2-Y$L"XT9N%M\UE51O@3T#:F\)82CO5\^ <8G5%;T1=%/@4##VW0)H)G
MLX]9/<J;C![%[\$,! N0OC[/Z@S.[!C>!8>\Q>FWYW&4M/#P(FIAT_ -,&%^
M!']]VE:C#^<TR>AX-JLK6"X==G\A+TL8!+X[4>/C0\ZZ<$+\^EF=P__"_.\]
MVM^/9GO3O6@'#\O_5/6'Z'G>\EP&D2Q]#(2-=NX-HD66P-S*$OY=-TF]B*HQ
M/1 <._9G> 84A-4C*;J3&\Y;.'\MOJ[.:/DQ3A!HW8SJ?)C15N,*9O-Z=)[
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MQ%#?N*6R-8B@Y)-AM!HDXTVR#*NK'#"]X^F<3/JU=ZBSY^3,M_$,!99<5G3
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M&KUXI60?4T5>[.6GW'3$.C I>-$5PQ'E7#-Y925">3@*,;-CRS"W1HV596P
MQ:ER!Q(EBZIIJ,Z!7=: %T%=([25;XK>*[N%)'!FZQ)X:?+,TR;RUDY2AGN
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MZ*/0.0&;O(;]76/3&TF2[CI>-KOW$\>N@]%/?+!$GP-7^Q+&I[7DYSH^(^9
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ME@4-)3-DYG7N!;*HR'J]SIYMBYSV-*9"9-_C^A*ZU9-0+C"/[P9DK;IUP>1
MF+S@!('%PS3%-N^=9DFG#ML0T6PEHEX2UG2O"$JX!/YRD11SG0>3YJBY(8]#
M80TK*TT_B9[Q*%)QF8*&$>J2+G5>T1)TWOA2]8N!+]T?BI;52\DP4C14HVN
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MLSVO J_HW,UC1=3!0!N)MI_$X(H>.H$G5X] P1@./D$RD&+5$K$$'##,"^-
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M)1U@?K/VNC=?<4HJA:X8)582,/4%37ZTK]]9Y8C[$J09#W-?Y9\B=R-67Y[
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ME=TPWD[<DI'D"%(>M75GZ3IZ _'7O)W=Y;!IIE7@?"Q@0;$P9'#S*G"#./%
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M6O+=460FTLC1W&22"N26Q,S&A#\*ZU3.FXN\*ARF:X50%\DEMZ90L5NQG5;
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M2^'WP[\?GNX?G>V]?GL8_+SWRV'P^O#P.#@]_.GH[/SP]/ @^!7>X3]O[_@
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M[8S#1,'N1E\&(231VY</2)!$@XL@&GS,BRLX%Z.$CT(T*A,YC.Y8(J!$S-?
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M)0K.RXCTJG=1^3$11M.'P6L5N?$\'#[Q+C2G8&/]9PH**.G^\D6>H.Y5PR/
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M#A8^. 1Y!,L(M[=H2[B&ULJX6T )A+-IOTK%/2-+>E5,LUC%+G54@ATG%%#
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M/DMSM>OL;2?W8LYR.H[ZVQAD=EJ&S%Q.LM]W;4SY9U2AE7"BC_R^C W<TEK
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M'FPBC!;Z,2"3"SDG'Z]R<IC<I%K?A:;=&A+=A>=+#:Q"9 ZMZYWBA_FH*]V
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M@0;';V.2YU1B<F*AJP1[ T&"9+^"Y:2J*<77 ILI@SZ6E%8?9^RV*J0%(<C
M4:H:#Z-VD27:+,)8_YA\!HP*NUD,-^F"TB(XB3MQ3K?&I\A"YM:3]J1/I_"@
MG<>/F_YTN87=$\:O)KD45KVJHG]HXH5&"U%?)@UIV):+':K@7-6P8.'%$Y"R
M/("!'0)KZ3VK8[GJ'BM]96XW;4N'LR)/9F*=>RTN$@[,"]G<#=2U;=9\Z.Z:
MZYTFCL[NZ,-&8"L)(E^#5@B*EO9I8"%QJ9[#2KG)QKJ@C!9*-AJHK%E?O1-A
MWR+60JY=XEL31X?U53D3U%?/"(DO4&/5JUSWK,/AX983,^,RA97!K"-VNACY
MR4"M.*DLTZ?6>[D*5T5EK:/TP(TOTR)STK@\MB>WS>-YP.<TYH;3=#O"8)_%
MBTG'QL22)%X?F+L(@CVY71#L75JAXX*S"=;AK[L-?QT7#$Y V7!G)O$R^ !&
MH6DJ_"* "\],93N69$;518N30PL@R<:PY;#8\9<%\0*5!JKRNPQ*K0IQD<2W
MLD']D)*3:>>K[U%'Y&UW(^8N6\:X;<O$L!$*MH)?[;":PJDR" >1-4-5!.LS
MMMR V&%"%3G[U9@5+(3-E\QX!P2(9CV:$K(D0%1UW$23=' 5^+/+GH0UR$C+
M"TE?8<7$)JX7SR"$!8-O0%JJA>QK"Z#5.Y]?A9/\^_MRDG^_=I*OG>1WYB1_
M6U1  ]"!AV!Z':#I.!VHN/([T!*-GF=GO#ANH4$!/,LHP\JOA=AAOAL+L0HX
MB#S7YDIUQE5&PZMY>+$[O+$S/$?G%@64ZQX&25ES BR^-(M4[453V=91]H&$
M)*W7<Z!=#R"D"@&@_CBGY%2=HSM;,+$-,D&U3TZ]R1I,:+DH!+Q0XNV5P@(@
MB0"V=R\TS2:<' 854'<Q"2SR-$A#$5XAJ0)+=)#TQM''!:[Y)KF1A.E' K<2
MO"=VCD<&XLD>*%$E2Y/I4B->/<&VTFQ@KB_[+*JG)=9+A,$9<'GZY6=*$\??
MDGK@0)A0]49!3BV$%TMB 2P3)#.=;T-&H#ZOK!9.4@.481"WM&Y3E!I]2_(]
M'']=%+Q6R'H$FEIK/!!YCX2AN.A" 2GR.QI)"85"J_J$.4Q@\S,&HOV&]1Z[
M.Y?PGBI=BH7=KJW'.GBZVR#PS@_=(^V6NV%+.KTMX4 Z6F@/(8HB8NLEXYEP
M[(>BPV:9V'TMD4^G*"6R<_$:J!28<,4>6\T4[ XK+5ZNSD:M.D%(S+MI(WW*
M5494UQ!/*4E5)U$]A$9$P-1Y4/J3HD,M@KN2N'Y984XF1=QA8.5(I0M04M:4
MZU3P33J0#YI056'&^S)3=G*BEIPR+6--TIERS*CL1U00724C)0]]>T U)>E1
M!0_2J,T!J*+Z AE2F3(9X<XZ'&&[!#WG7Q9=L:M19>^'=OFI'8-H3>IG2CG%
MGV8CR@ S=!?&<_72R$3S=8J9D[G <UQZ6;1'6$5KK1V%2]+2(?>ZC\'S)XX%
M@PKL^X<[4O P$0&S;<UQ#KF6*IOI)!'<YS-N2<5>XQSK76%ST,;!:"I&:(@S
MD#\"\VNQG#3)V0O.!Z *$/VQ!5LTS36&HX7!9?IJV?B4G+OKWN$&^0:Z,KN@
M?D%%J2N:3.H&O>";Q[NZIE!17;;RV'COJ$8.SOM5I+I^22V,%-K9<92V7![2
MUV:6!A@&B_+B89O3J4=>ZQD1<*N4_6E=LBRF(U5;7I2C*$]_5XE%=GVWU&]W
M5#TZ9=*\.2UT.#=$:S (3)FUFAKU#V C,/E(?)4^0+(4?92O"G@.!#.%7S4X
ML:X#U$V1W6AH?RIR6CA839L%SLFH  $_C"C(4R$RN;$HRY+2R)# 4N+.$5EZ
M@Y5';BGJZII(XL9MXH(5?EVAQ$*^5G6:QOVJ*KT]CZ_+V4980@ECACV3E@0M
MT_3JXF-'29Z44685@&*>W:B@;=2P4=')*F8S ](2QXT\T&L?'H=:6E#<CRNU
M=&\^A0O>#+W-Z1V@W\T5&_SJD /ZKI2>(YH]6E/=+&L!$G*V8_**K>/29LF(
MJS!H,\]E\,OI(YXXXF9@6/!/M9KE@(L^+(4C&>*2DQ)8]#&;R9JPR*)(2L8Y
ML*<3%9C!5")P2/FCE 51'-"'TB_BF<H(_PT.9Q5SIH.2*:&A9NAJ.DFNUM0@
M<!;J/+)^!R\;-:'FUF[TS^E&?WI?;O2G:S?Z-^Y&OZ:6]!I%@1::EFN+K8@K
M'Q4]MR':5 9F5\*NZ?S4T:^'F)?!3FAIANTI8/-YKTFKH+\T][39L*0,AZT"
M:A&/QIRV(D;5:0ZW7CV>NM+>M;F)3C^!$E-2,=?;Z,H J/YGFE2\QK"N [E"
MDEZM8(9"V0"9C/F!TN:*=47@M<"=Z_9(BTZA&]'[I=0+;4-^OGB1Y*FM.?><
M*0]OP382G/\H646UJ/](\W\4Y4=C.#"RAC)7I-@U2U1[\"%L259&T?>@=EMP
M&$F/D1EW$[$\ Z0WH4(K7N &O5PZ5$U"(<Y);NQ\J\6=W^+6L_(WKBZX,*1/
M-HU1C@6]2A7/LB<M+96)3-C>("8S5!$I<T,@ D+MJ@K9(R<X-2$]+Z??Q@ER
M(IP&#*N8)6+C8&5(U3.K*H <"?;F .NM@G>:$E].ZB(_08*='M"'-D75KTH9
M;%*NVQ?M72VCLQ""FY6697)9##AJ-NV/T[HRQJB\V>4A*FWXAH,(@]<%VY#P
MX;LHO\!:98/3A+P[ML#*)/=\,A6$*%80F2%;R<G*_Z*;6&@?A@@+9R?(W#DM
M;S"M*NU7X[A>"VW('I= I>QA 7Y"S;X4T8,TQ*Z%)OAB=G:H4.#2L9V]B$^9
M4-]MJ9)U,#A\RNO&<$3LT'(@=K^8.G>.N8A46DA3!QN"1\O)DPP_IXEQ=9E[
M%VT9)HN> &HCEU*$10^I*LV4$BD*4I_W$\I^)%!O0[WY,^FCX95F7)<Z*"8&
MP^@RC;SL17%EP!\$=X:>3^+4>-(U!-(&;18=&T? #_FJ9YKJ,>.2<C-!34M5
M>CI1C>L:*@DU-XT8>]M82R;$:OC!R<? .=3:V=]!6551H5CM<<%%VX*6Y(?S
M'+!^,O@5Z:^DJI]C=CAW"D^H=\E5[(CAS'=<]3'6TA%K!89/<4K)[&>BJ9DQ
M,R/=3 0?+K*WN&0L$F]W$8%;O#,L?))+V0O\LM2)2+:^PDH\3\?]:5D9YVEA
M#7MHL7SCT)>BO0K3U':>OC#MDPJ)?%2UUTX)SA@F!\2VO+U$O6 D_C"8PT0U
M,""G<UF@\\OM_-1R$-8*W)TV%O *94QF.A#_8UY<94D\4B>W)8@F6>2=,0Q[
MYZ9#J4M0K,I WRD@ 94ZBCDA"#C9R).4Y'7JC^%4G4@*$#>Q&F,%%FWOIJCV
M\%I6;SM]%3Z6'^[+Q_+#VL?RC?M8[K)#R'&1DYK'B62'(MR851X7I(E6HCI%
MF92W, !E%I&2;>%5:L9H5 U+J\]5W*"VXAGB5IDDI4"#1H$,IW";\Y06L" <
M.;(C[,1[D=N53KF?%%=238YQ<'2:=*2X:\A/KT6!S=7]F B' )!B*$'@28@
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M_*(?'SRA@X87:%J:J7\*#(5NPHV\(8(4QCOOQ"-GR(]?L/S&63RL8SU?X$1
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M44O)NOD.'$]\U@\N1J8^9"COQ@DEJQT6B9-KILO2,N=_O2,,W+5>B(AHX0B
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M>+;*I%[(E\!91^H1>+PC&E6)9_QG=\JO%7G42^B>&YA0BF*(G(BU-0,A@$P
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M=-SZ+P=[=P^_#SOBZV,R*# %@9,LX.\;M*59L:EF65HC%>DO6 *PQT#M5Q^
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M8$R/HCRTI=QQ-$LQ9F0G;,A7/V?%L/>;"XHGN1>HZ(_X;Y4SK"$_*S)D;;J
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M%#\H<=GN#MRS;8,I.*;>N&N[$"H#G4 FL*U#!J^!4U,Y@EQ=-0 7@%+SC P
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MMZQGM]1[ATUQ]-5+TNK"2BV##QKEJW#;()3F/4W3U^'KR8!1X1Q?O^"?X*-
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ML>@8APD!7K \T KP>*\Z;GN5!K1S+3R4.-@$SMC__@.U>[8T !N]EK8;CVN
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MA>?XC$*'LX46HPE;F  #M8V=MQ%ZNGFCU:.#+4QS>OH8#L?WBU(9K38 :,^
MJV4CIM"MVB,Z!HK;?-%&1N7O\SK,.LQ!M2T-I76R.=>E?SHIOTFZ=M @X" G
MUL)C*DU65(D!O6T0+JW=IV#$:S5"MH*IMK<>;GL0I7VT, M=9,']\.3D>6U
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MBWQJ%'G"CJ4"#ZN?W.0G)CM*=V/%.KX3/(EBH7<)NJ7D5DUL1[9K*#)P-75
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ML.?3MM]_S?EZ J]1"WEA(.[;H6$"1>;W1_=:+G:/9>(@O;FLL_U?!B+DYMQ
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MQX\:5[X'-&8)IM.._WT8=(>]?M_W,H%H@@BCT/$I\S]]_/67#[\%P1>@P)&
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MA&D+IY2QZYBN-W,]6<CL8^^VJL^T72NEFQ6T=S:] T.9K8R(2*232,*B;^T
M^;_-A)UQF\$ L/U)$E4Q5S6TRL%![7"#P7KKQ!G0^VZ8H)M2K%8I5<LUJP=:
M=?_ J-=7*AK9I(*?4IVWU.K8+CPGX?)2D8CKD6M_ O'!KX''A<5-) 8XCLB
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ML/E\X^!%:R$<+<<FB;% <Q6/Q#H+,+*H%\.FDYM$<08[KM"W0/*MO623('?
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M+=S=9;=<G3"VN#!M5S!PJZ"EEW1.RI4H-TH&6^!@&2@YZ"ZX3A_=MCPQCEW
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M*F-;;$9$YS3CW"BKXFNBB'"9MB+$CRZ2AAE=!(- *DSQHLQ2A.1&!P"E/HL
M;4]LW:)IEMS<D('(1N(#4CE$LLGN>&)1!BW?E2%H24[UV<Q7@E+)],I(1)H9
MYV$!R.2^"@OW]7HDY.#ZXJH_?H=,IL;NJ! 6S@ =D'VEN&!%1+AE%+(3!R7T
M6:2E4,:*0P@C\/@(!=,_FZ2@C7W)^KA4W5W$8T3A5?'W1DDOQ;"_B #\V%'_
ML:/^8T?]F8I"=7!B.U$3.HL/N\N/?2A_B'XSK'&^XD*1DK\G$;I'?U#]D2JT
MT8AN)^)/!MI&75FSX[#]LKEFWMI[2-:?&J>_QP)F?5K08F;X ;"&RE'PKWY
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M"%![PMF(+,XP7,N_OK&[4O1 +>^;]L^RBI[KCX==M/H#;7&@*O/ UY,>Y(J
M@%]"S"?^U&[^/U!+ 0(4 Q0    ( /E&EEO&Q\I0;58  *@I @ -
M      "  0    !E>%\Y,#$T-S4N:'1M4$L! A0#%     @ ^4:66S("7%>Q
M6   (TP"  T              ( !F%8  &5X7SDP,30W-BYH=&U02P$"% ,4
M    " #Y1I9;*832'(L4  #1>@  #0              @ %TKP  97A?.3 Q
M-#<W+FAT;5!+ 0(4 Q0    ( /E&EEO/QBE<B5@  %,Q @ -
M  "  2K$  !E>%\Y,#$U-3$N:'1M4$L! A0#%     @ ^4:66X*XJ8.O%P
MUQ@   P              ( !WAP! &QO9V]S;3 Q+FIP9U!+ 0(4 Q0    (
M /E&EELX+3 J@ ,  !H.   1              "  ;<T 0!M8G)X+3(P,C4Q
M,C(Q+GAS9%!+ 0(4 Q0    ( /E&EENDSOCOV00  .8L   5
M  "  68X 0!M8G)X+3(P,C4Q,C(Q7V1E9BYX;6Q02P$"% ,4    " #Y1I9;
MS8H<2_<%  !$/   %0              @ %R/0$ ;6)R>"TR,#(U,3(R,5]L
M86(N>&UL4$L! A0#%     @ ^4:66VIR$#9V!   ?BT  !4
M ( !G$,! &UB<G@M,C R-3$R,C%?<')E+GAM;%!+ 0(4 Q0    ( /E&EEM^
MOJUOCQ4  .V%   3              "  45( 0!M8G)X,C R-3$R,C%?.&LN
9:'1M4$L%!@     *  H ;P(   5> 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>mbrx20251221_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mbrx-20251221.xsd" xlink:type="simple"/>
    <context id="d20258K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2025-12-21</startDate>
            <endDate>2025-12-21</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20258K" id="ixv-289">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20258K" id="ixv-290">0001659617</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20258K" id="ixv-300">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20258K" id="ixv-301">2025-12-21</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20258K" id="ixv-302">MOLECULIN BIOTECH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20258K" id="ixv-303">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20258K" id="ixv-304">001-37758</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20258K" id="ixv-305">47-4671997</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20258K" id="ixv-306">5300 Memorial Drive, Suite 950</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20258K" id="ixv-307">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20258K" id="ixv-308">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20258K" id="ixv-309">77007</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20258K" id="ixv-310">713</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20258K" id="ixv-311">300-5160</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20258K" id="ixv-312">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20258K" id="ixv-313">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20258K" id="ixv-314">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20258K" id="ixv-315">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="d20258K" id="ixv-316">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="d20258K" id="ixv-317">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20258K" id="ixv-318">MBRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20258K" id="ixv-319">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
